Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies.

Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies.

Journal: Expert opinion on drug safety
Published: October 13, 2025

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.

Journal: Journal of neurology
Published: July 28, 2025

Neutropenia Associated With B Cell-Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

Neutropenia Associated With B Cell-Depleting Therapies in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 19, 2025

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.

Journal: Frontiers in immunology
Published: April 09, 2025

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment.

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-Cd20 Monoclonal Antibodies for Multiple Sclerosis Treatment.

Journal: Current neuropharmacology
Published: April 07, 2025

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.

Journal: CNS drugs
Published: March 16, 2025

A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.

A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma.

Journal: British journal of haematology
Published: January 17, 2025

Exploring Public Interest in Multiple Sclerosis and Its Treatment Measures in the United States: A Google Trends Analysis.

Exploring Public Interest in Multiple Sclerosis and Its Treatment Measures in the United States: A Google Trends Analysis.

Journal: Cureus
Published: November 27, 2024

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.

Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series.

Journal: Frontiers in immunology
Published: November 12, 2024

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Treatment of Relapsed/Refractory CLL Patients With PI3Kδ Inhibitor and Anti-CD20 Antibody Rapidly Decreases Tumor Burden but Could Induce Resistance.

Journal: American journal of hematology
Published: September 24, 2024

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials.

Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials.

Journal: Frontiers in neurology
Published: August 14, 2024

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.

Journal: Frontiers in neurology
Published: July 30, 2024
Showing 1-12 of 90

Last Updated: 10/31/2025